Juventas Therapeutics has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal cell-Derived Factor-1 (SDF-1). For more information please contact Dr. Joe Pastore at jpastore@juventasinc.com